{"entity":{"id":"nct07178730","kind":"trial","name":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","aka":["ADAPT-TN-IV"],"tldr":"A phase 3 trial of sacituzumab govitecan in triple-negative breast cancer, run by Women's Cancer Study Group GmbH, not yet recruiting.","summary":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer. ClinicalTrials.gov record last updated 2026-08-05: not yet recruiting. Enrollment is planned at 765 participants. Primary completion is estimated at 2033-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications. Registered interventions: Sacituzumab govitecan, Pembrolizumab 25 mg/1 ML Intravenous Solution [KEYTRUDA], SoC Chemotherapy. Registered primary measures: Cohort I: 3-year event-free survival (EFS); Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to event-free survival (EFS); Cohort II: superiority of neoadjuvant treatment with SG+PEM vs. SoC with regards to pathological complete response (pCR) rates.","status":"planned","asOf":"2026-10-06","links":[{"label":"ClinicalTrials.gov NCT07178730","url":"https://clinicaltrials.gov/study/NCT07178730"}],"tags":["ctgov-ingest","tnbc-deep-dive"],"related":[],"cancers":["tnbc-early"],"sections":[],"technologies":["adc"],"targets":["trop2"],"drugs":["sacituzumab-govitecan"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["ClinicalTrials.gov record last updated 2026-08-05: not yet recruiting. Enrollment is planned at 765 participants. Primary completion is estimated at 2033-03-31. No tabular results are posted on ClinicalTrials.gov; this does not exclude separate publications."],"nct":"NCT07178730","phase":"3","setting":"NeoAdjuvant Therapy Comparing Sacituzumab Govitecan+Pembrolizumab vs. SoC Chemotherapy in Clinical Stage II-III, Triple-negative Early Breast Cancer","sponsor":"Women's Cancer Study Group GmbH","participation":[{"nct":"NCT07178730","source":"https://clinicaltrials.gov/study/NCT07178730","fetchedAt":"2026-10-07T16:55:32.313Z","studySha256":"d01cd38b904b799ccb6389a217ec6c724d568bac225a1422dedc572e1796e08f","overallStatus":"NOT_YET_RECRUITING","lastUpdatePosted":"2026-08-05","leadSponsor":"Women's Cancer Study Group GmbH","collaboratorCount":1,"minimumAge":"18 Years","sex":"ALL","healthyVolunteers":false,"hasEligibility":true,"enrolment":765,"enrolmentType":"ESTIMATED","siteCount":26,"recruitingSiteCount":0,"countries":["Germany"]}],"started":"2026-08-30","startedType":"estimated","enrolled":765,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct07178730/","neighbours":{"cancer":[{"id":"tnbc-early","kind":"cancer","name":"Early triple-negative breast cancer","route":"/cancers/tnbc-early/"}],"technology":[{"id":"adc","kind":"technology","name":"Antibody-drug conjugate (ADC)","route":"/technologies/adc/"}],"target":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/"}],"drug":[{"id":"sacituzumab-govitecan","kind":"drug","name":"Sacituzumab govitecan","route":"/drugs/sacituzumab-govitecan/"}],"term":[{"id":"tnbc-trials-open-today","kind":"term","name":"Triple-negative breast cancer trials open today (registry snapshot and UK sites)","route":"/terms/tnbc-trials-open-today/"}]}}